Chimeric antigen receptor modified T cell therapy for B cell malignancies.
about
Plasmablastic Lymphoma: A Review of Current Knowledge and Future DirectionsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaGene therapy for cancer: present status and future perspectiveAnti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Radiation therapy for primary breast lymphoma in male gynecomastia: a rare case report and review of the literature.Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.Site-specific integration of CAR gene into Jurkat T cells with a linear close-ended AAV-based DNA vector for CAR-T engineering.Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.Current status and future directions of cancer immunotherapy.
P2860
Q26781831-7D4912AB-0AC5-42D6-95BE-2C0A226B1889Q28081600-0B67D277-1EBD-4E05-A280-CF86AD60C8ABQ35673900-05A2F88E-F76F-44B7-9F81-5764B61B88DCQ38538645-B9891716-8DF9-494F-86BA-7BB6360A55B9Q38786626-80F0D0A3-23BC-4D32-9AFB-9E9293A5DE86Q38787449-17E0E1B9-58C5-473C-B5B3-57DAD6F340B1Q38844304-BC29DC8F-02D0-4569-B3AD-5F57F49A0492Q39007364-A3F44958-A6D9-48F6-BD79-9E9542E917EAQ40714447-57918F43-2982-4D63-BB16-FD0875AD0A57Q43407962-0FB9AB0E-E3DE-435A-A2BA-EADE29F5E86FQ46018826-A925B70E-8E45-49DD-BC28-523551972C8FQ50027149-E17EDEE7-0162-4FA0-BA60-CD4801F4A33AQ50041712-0BC05EEB-FB22-496F-B72C-3E66B6A9EB00Q50426810-EA8DDF96-5934-4B7A-9D3E-871F4BCFCC32Q55070491-452445B9-D376-4E1F-ADB5-2C6E2E203146
P2860
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
@en
type
label
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
@en
prefLabel
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
@en
P2860
P1476
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
@en
P2093
Cameron J Turtle
P2860
P2888
P304
P356
10.1007/S12185-013-1490-X
P577
2013-12-14T00:00:00Z
P5875
P6179
1021549038